A
-
Antibiotic resistance
CORRELATION BETWEEN BIOFILM OF DENTAL MICROBES AND ANTIBIOTIC RESISTANCE, IN VITRO STUDY [Volume 68, Issue 2, 2023, Pages 188-205]
-
Anti-cancer agents
PYRIDINE DERIVATIVES AS ANTICANCER AGENTS: FDA-APPROVED DRUGS AND PROMISING REPORTED COMPOUNDS [Volume 68, Issue 2, 2023, Pages 64-81]
-
Anti-cancer agents
VEGFER-2 INHIBITORS AND QUINAZOLINE-BASED ANTICANCER AGENTS [Volume 68, Issue 2, 2023, Pages 111-129]
-
Atropine Sulfate (AS)
PREPARATION AND CHARACTERIZATION OF ATROPINE SULFATE ORODISPERSIBLE TABLETS [Volume 68, Issue 2, 2023, Pages 43-63]
-
Aurora
EXPLORING THE PROTEIN KINASE INHIBITORY ACTIVITY OF QUINAZOLINES AS ANTICANCER AGENTS: FDA-APPROVED DRUGS AND PROMISING REPORTED COMPOUNDS [Volume 68, Issue 2, 2023, Pages 82-110]
B
-
BCR-ABL
AN OVERVIEW OF QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS [Volume 68, Issue 2, 2023, Pages 130-158]
-
Biofilm
CORRELATION BETWEEN BIOFILM OF DENTAL MICROBES AND ANTIBIOTIC RESISTANCE, IN VITRO STUDY [Volume 68, Issue 2, 2023, Pages 188-205]
-
Biological targets
PYRIDINE DERIVATIVES AS ANTICANCER AGENTS: FDA-APPROVED DRUGS AND PROMISING REPORTED COMPOUNDS [Volume 68, Issue 2, 2023, Pages 64-81]
C
-
Cancer
FORMULATION AND CHARACTERIZATION OF THERMOSENSITIVE CHITOSAN HYDROGEL LOADED WITH ERLOTINIB: FULL FACTORIAL DESIGN OF RELEASE DATA [Volume 68, Issue 2, 2023, Pages 1-27]
-
Chitosan
FORMULATION AND CHARACTERIZATION OF THERMOSENSITIVE CHITOSAN HYDROGEL LOADED WITH ERLOTINIB: FULL FACTORIAL DESIGN OF RELEASE DATA [Volume 68, Issue 2, 2023, Pages 1-27]
D
-
Dental bacteria
CORRELATION BETWEEN BIOFILM OF DENTAL MICROBES AND ANTIBIOTIC RESISTANCE, IN VITRO STUDY [Volume 68, Issue 2, 2023, Pages 188-205]
E
-
Erlotinib
FORMULATION AND CHARACTERIZATION OF THERMOSENSITIVE CHITOSAN HYDROGEL LOADED WITH ERLOTINIB: FULL FACTORIAL DESIGN OF RELEASE DATA [Volume 68, Issue 2, 2023, Pages 1-27]
H
-
Hsp90
AN OVERVIEW OF QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS [Volume 68, Issue 2, 2023, Pages 130-158]
I
-
ICH
DEVELOPMENT AND VALIDATION OF LC-MS METHOD FOR SIMULTANEOUS DETERMINATION OF PYRIMETHAMINE AND SULFADOXINE IN THE PHARMACEUTICAL PREPARATION [Volume 68, Issue 2, 2023, Pages 159-171]
-
In vitro release
FORMULATION AND CHARACTERIZATION OF THERMOSENSITIVE CHITOSAN HYDROGEL LOADED WITH ERLOTINIB: FULL FACTORIAL DESIGN OF RELEASE DATA [Volume 68, Issue 2, 2023, Pages 1-27]
L
-
LC-MS method
DEVELOPMENT AND VALIDATION OF LC-MS METHOD FOR SIMULTANEOUS DETERMINATION OF PYRIMETHAMINE AND SULFADOXINE IN THE PHARMACEUTICAL PREPARATION [Volume 68, Issue 2, 2023, Pages 159-171]
N
-
Nanoparticles
FORMULATION AND CHARACTERIZATION OF THERMOSENSITIVE CHITOSAN HYDROGEL LOADED WITH ERLOTINIB: FULL FACTORIAL DESIGN OF RELEASE DATA [Volume 68, Issue 2, 2023, Pages 1-27]
O
-
Organophosphate (op)
PREPARATION AND CHARACTERIZATION OF ATROPINE SULFATE ORODISPERSIBLE TABLETS [Volume 68, Issue 2, 2023, Pages 43-63]
-
Orodispersible tablets (ODT)
PREPARATION AND CHARACTERIZATION OF ATROPINE SULFATE ORODISPERSIBLE TABLETS [Volume 68, Issue 2, 2023, Pages 43-63]
P
-
Premature Ejaculation
FORMULATION AND CHARACTERIZATION OF DIFFERENT TOPICAL HYDROGELS LOADED WITH SILDENAFIL CITRATE [Volume 68, Issue 2, 2023, Pages 28-42]
-
Pyridine derivative
PYRIDINE DERIVATIVES AS ANTICANCER AGENTS: FDA-APPROVED DRUGS AND PROMISING REPORTED COMPOUNDS [Volume 68, Issue 2, 2023, Pages 64-81]
-
Pyrimethamine
DEVELOPMENT AND VALIDATION OF LC-MS METHOD FOR SIMULTANEOUS DETERMINATION OF PYRIMETHAMINE AND SULFADOXINE IN THE PHARMACEUTICAL PREPARATION [Volume 68, Issue 2, 2023, Pages 159-171]
Q
-
Quinazoline
EXPLORING THE PROTEIN KINASE INHIBITORY ACTIVITY OF QUINAZOLINES AS ANTICANCER AGENTS: FDA-APPROVED DRUGS AND PROMISING REPORTED COMPOUNDS [Volume 68, Issue 2, 2023, Pages 82-110]
-
Quinazoline
VEGFER-2 INHIBITORS AND QUINAZOLINE-BASED ANTICANCER AGENTS [Volume 68, Issue 2, 2023, Pages 111-129]
-
Quinoline
AN OVERVIEW OF QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS [Volume 68, Issue 2, 2023, Pages 130-158]
R
-
Rabies Virus
MONITORING OF RABIES IMMUNE STATUS IN EXPERIMENTALLY VACCINATED PUPPIES [Volume 68, Issue 2, 2023, Pages 172-187]
S
-
Serine/threonine kinases
EXPLORING THE PROTEIN KINASE INHIBITORY ACTIVITY OF QUINAZOLINES AS ANTICANCER AGENTS: FDA-APPROVED DRUGS AND PROMISING REPORTED COMPOUNDS [Volume 68, Issue 2, 2023, Pages 82-110]
-
Sulfadoxine
DEVELOPMENT AND VALIDATION OF LC-MS METHOD FOR SIMULTANEOUS DETERMINATION OF PYRIMETHAMINE AND SULFADOXINE IN THE PHARMACEUTICAL PREPARATION [Volume 68, Issue 2, 2023, Pages 159-171]
T
-
Topoisomerases
AN OVERVIEW OF QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS [Volume 68, Issue 2, 2023, Pages 130-158]
-
Tubulin inhibitors
AN OVERVIEW OF QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS [Volume 68, Issue 2, 2023, Pages 130-158]
-
Tyrosine kinases
EXPLORING THE PROTEIN KINASE INHIBITORY ACTIVITY OF QUINAZOLINES AS ANTICANCER AGENTS: FDA-APPROVED DRUGS AND PROMISING REPORTED COMPOUNDS [Volume 68, Issue 2, 2023, Pages 82-110]
V
-
Vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors
VEGFER-2 INHIBITORS AND QUINAZOLINE-BASED ANTICANCER AGENTS [Volume 68, Issue 2, 2023, Pages 111-129]
-
VEGFR
EXPLORING THE PROTEIN KINASE INHIBITORY ACTIVITY OF QUINAZOLINES AS ANTICANCER AGENTS: FDA-APPROVED DRUGS AND PROMISING REPORTED COMPOUNDS [Volume 68, Issue 2, 2023, Pages 82-110]
-
VEGFR
AN OVERVIEW OF QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS [Volume 68, Issue 2, 2023, Pages 130-158]
Your query does not match with any item